CAS 91714-94-2|Bromfenac
Introduction：Basic information about CAS 91714-94-2|Bromfenac, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Bromfenac | ||
|---|---|---|---|
| CAS Number | 91714-94-2 | Molecular Weight | 334.165 |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 562.2±50.0 °C at 760 mmHg |
| Molecular Formula | C15H12BrNO3 | Melting Point | -129ºC |
| MSDS | / | Flash Point | 293.8±30.1 °C |
Names
| Name | bromfenac |
|---|---|
| Synonym | More Synonyms |
Bromfenac BiologicalActivity
| Description | Bromfenac is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac can be used in ocular inflammation research[1]. |
|---|---|
| Related Catalog | Research Areas >>InfectionResearch Areas >>Inflammation/ImmunologySignaling Pathways >>Immunology/Inflammation >>COX |
| Target | Human COX-1:5.56 nM (IC50) Human COX-2:7.45 nM (IC50) |
| In Vitro | Bromfenac (0-80 μg/mL; 24 h) can inhibit transforming growth factor-β2-induced epithelial-mesenchymal transition in HLEC-B3 in a concentration-dependent manner[2]. Bromfenac (80 μg/Ml; 48 h) inhibits transforming growth factor-β2-induced epithelial-mesenchymal transition in human anterior capsules[2]. Cell Viability Assay[2] Cell Line: Transforming growth factor-β2-treated human anterior capsules Concentration: 80 μg/mL Incubation Time: 48 hours Result: Suppressed transforming growth factor-β2-induced epithelial-mesenchymal transition in primary LECs. Cell Migration Assay [2] Cell Line: HLEC-B3 cells Concentration: 0, 20, 40, 60, and 80 μg/mL Incubation Time: 24 hours Result: Suppressed transforming growth factor-β2-induced cell migration in HLEC-B3 cells, and exhibited inhibition of the over-expression of epithelial-mesenchymal transition markers. |
| In Vivo | Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats[3]. Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats[3]. Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs[3]. Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats[3]. Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice[3]. Bromfenac (eyedrop instillation; 1 μL (0.09%) per eye; twice-daily; 4 w) partially reduces corneal staining, and becomes so more slowly by the 4-week time point[4]. Animal Model: Male Sprague-Dawley rats (150-250 g) are injected carrageenan[3] Dosage: 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) Administration: Rubbed onto the backs before 1-72 h of injected carrageenan Result: Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%. Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%. Animal Model: Male injected with Salin or BTX-B[4] Dosage: 1 μL (0.09%) per eye Administration: Eyedrop instillation; 1 μL (0.09%) per eye; twice-daily; 4 weeks Result: Improved the corneal fluorescein staining score later at 4 weeks after treatment. |
| References | [1]. Tetsuo Kida, et al. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS One. 2014 May 5;9(5):e96481. [2]. Xiaobo Zhang, et al. Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification. Bioact Mater. 2021 Jul 23;9:343-357. [3]. Nolan JC, et, al. The topical anti-inflammatory and analgesic properties of bromfenac in rodents. Agents Actions. 1988 Aug; 25(1-2): 77-85. [4]. Kaevalin Lekhanont, et al. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. J Ocul Pharmacol Ther. 2007 Feb;23(1):27-34. |
Chemical & Physical Properties
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 562.2±50.0 °C at 760 mmHg |
| Melting Point | -129ºC |
| Molecular Formula | C15H12BrNO3 |
| Molecular Weight | 334.165 |
| Flash Point | 293.8±30.1 °C |
| Exact Mass | 333.000061 |
| PSA | 80.39000 |
| LogP | 2.72 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.663 |
| InChIKey | ZBPLOVFIXSTCRZ-UHFFFAOYSA-N |
| SMILES | Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1 |
| Storage condition | 2-8°C |
Safety Information
| Hazard Codes | Xi |
|---|---|
| HS Code | 2922509090 |
Customs
| HS Code | 2922509090 |
|---|---|
| Summary | 2922509090. other amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Synonyms
| Bromfenacum [Latin] |
| Bromfenac [INN] |
| Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- |
| bromfenacum [INN_la] |
| 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid |
| bromfenac |
| [2-Amino-3-(4-bromobenzoyl)phenyl]acetic acid |
| Bromfenacum |
| Bromfenaco [Spanish] |
| Duract |
| Xibrom |
| Bromfenaco |
